Navigation Links
Pharsight to Present on Oncology Modeling and Simulation at PAGE Annual Meeting
Date:6/12/2008

Dr. Laurent Claret Will Present Case Studies on the Value of Drug-Disease Modeling to Predict Efficacy and Survival Benefits of Anticancer Agents

MOUNTAIN VIEW, Calif., June 12 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Laurent Claret, Ph.D., senior scientist, Pharsight Strategic Consulting Services, will speak to members of the pharmaceutical and biotechnology industries attending the Population Approach Group in Europe (PAGE) 17th Annual Meeting. The PAGE meeting will be held at the Medical School of Marseille in Marseilles, France from June 18-20, 2008.

Dr. Claret will present two oncology case studies during a dedicated conference session on applications in model-based development:

-- June 18: A Modeling Framework to Simulate Xeloda Dose Intensity and

Survival in Colorectal Cancer. Dr. Claret will present this case study

as part of an oral conference session on the strategic use of modeling

and simulation in oncology. The session will include applied examples

of drug-disease modeling and will describe research on how

quantitative, model-based approaches have been used to support dosing

decisions of anticancer therapies in clinical practice. Rene Bruno,

Ph.D., managing director, Pharsight Strategic Consulting Services,

Europe, serves as conference chair for the oncology session.

-- June 19: Modeling and Simulation to Assess the Use of Change in Tumor

Size as Primary Endpoint in Phase II Studies in Oncology. Dr. Claret

will present this case study in collaboration with Pharsight's client,

a global pharmaceutical company, as part of a poster session on

model-based applications in oncology. The session will describe

research on a number of model-based approaches to support drug

development in oncology, including tumor progression modeling and

clinical trial simulations to predict efficacy and survival benefit of

anticancer agents.

Dr. Claret and Dr. Bruno also contributed to a model-based analysis of tumor size measurements obtained in clinical oncology studies involving combination chemotherapy, as part of an ongoing collaboration between Pharsight and the University of Aix-Marseille School of Pharmacy. This analysis will be presented by Pharsight colleagues at the University of Aix-Marseille as part of the PAGE poster session on model-based applications in oncology.

"Model-based drug development continues to show value for enhancing understanding of complex diseases in quantitative terms, and for improving the confidence of drug development decisions," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "Application of drug-disease models to simulate expected clinical response of new anticancer therapies can support critical oncology program strategies, particularly in light of the high failure rate in late-stage trials. The use of predictive drug-disease models can serve as a quantitative framework to support programmatic decision-making and enhance study design decisions. Pharsight is pleased to continue its active participation at the PAGE Annual Meeting, this year as a main conference sponsor, and we look forward to sharing our experience with industry colleagues and fellow practitioners of modeling and simulation."

Additional information about PAGE can be found at http://www.page-meeting.org.

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this document are trademarks or registered trademarks of their respective companies or organizations.


'/>"/>
SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Pharsight Files Application for Nasdaq Capital Market Listing
2. Pharsight to Host European Software Conference
3. Pharsight Expands Global Consulting Services Teams
4. Pharsight Achieves $7.3 Million in Quarterly Revenue
5. Pharsight to Present at DIA Cardiac Safety Conference on December 4, 2007
6. FDA and Pharsight Continue to Collaborate Under CRADA
7. Pharsight to Host Webinar on Hepatitis C Virus (HCV) and HIV Drug-Disease Modeling
8. Pharsight to Present at eClinical Forum
9. Pharsight Signs New Diabetes Meta-Database Customer
10. Pharsight Announces Fiscal Fourth Quarter 2008 and Year End Earnings Release Date and Conference Call
11. Pharsight Strengthens Senior Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 08, 2016 , ... After enjoying record-breaking attendance at its ... its 33rd Annual Issues & Research Conference, March 2-3, 2017, at the ... conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." ...
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation ... adherence, and other pharmacist-delivered patient care services, has announced the promotions of Karen ... to vice president of sales. , Litsinger joined Mirixa in 2008 after ...
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) and The Chopra Center ... loss and wellness program, at their world headquarters of Omni La Costa Resort & ... results to anyone seeking weight loss, personal development, a healthy lifestyle, or mental and ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... has been recognized for adherence to the highest standards of trauma, maternity, cancer ... announced the center's president and CEO, Dr. Daniel Messina. , Among the recognitions, ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Care Act. Dr. Botelho advocates for the mass media launching of story movements ... ongoing opportunities to share their unfortunate experiences; such a movement can generate the ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Allergy Diagnostics Market: Scope and Methodology ... are used to determine the presence of allergens ... etc. in the samples by determining the presence ... report on global allergy diagnostics market, analyzes the ... report consists of an executive summary that provides ...
(Date:12/8/2016)... Mass. , Dec. 8, 2016   ... that Nationwide Children,s Hospital signed a ... and accelerate the development of new cures. ... organizations representing over 57 million patients globally, biopharmaceutical ... working together to improve protocol design, site selection, ...
(Date:12/8/2016)... True Health Diagnostics today announced a ... and management expertise to hospital systems throughout ... doctors and patients to benefit from state-of-the-art biomarker ... Logo - http://photos.prnewswire.com/prnh/20161208/447162LOGO ... to contain costs, have struggled to keep up ...
Breaking Medicine Technology: